Is Landogrozumab legal in Australia?

The clearest test in the whole field. In 201 older adults who had fallen, it added 0.43 kg of lean mass at p below 0.0001 and moved two of about seven physical performance measures.

This is the trial to read if you want to understand what myostatin inhibition actually delivers, because it was run in exactly the population the idea is meant to help: older adults who were weak and who had fallen. The body composition result is unambiguous.

Mechanism: A humanised monoclonal antibody neutralising myostatin, blocking its signalling through activin type II receptors and the SMAD2/3 pathway that suppresses muscle protein synthesis. Same target as stamulumab, engineered for higher potency.

Regulatory history: Never approved. Eli Lilly did not advance it past phase 2.

Registers or lists therapeutic goods on the ARTG and schedules substances in the Poisons Standard. Many peptides are Schedule 4 (prescription only), so possession without a prescription and personal importation are restricted even when no product is registered.

The classification above is the The Longevity Archive reading of Therapeutic Goods Administration listings for Landogrozumab at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.